{"DataElement":{"publicId":"6384982","version":"1","preferredName":"Best Overall Lesion Response irRECIST Type","preferredDefinition":"Text to represent the best overall  disease response recorded from the start of the study treatment until the end of treatment using the  Immune-related Response Evaluation Criteria in Solid Tumours (irRECIST).","longName":"BEST_OVR_RESP_irRECIST_TP","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3861381","version":"1","preferredName":"Best Overall Lesion Response","preferredDefinition":"Having the most positive qualities._Including everything._A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part._Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"3861379v1.0:2193203v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"3861379","version":"1","preferredName":"Best Overall Lesion","preferredDefinition":"Having the most positive qualities.:Including everything.:A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","longName":"C25432:C25605:C3824","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Overall","conceptCode":"C25605","definition":"Including everything.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E48AB905-C87B-6390-E040-BB89AD43301A","latestVersionIndicator":"Yes","beginDate":"2013-08-22","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-08-22","modifiedBy":"ONEDATA","dateModified":"2013-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2193203","version":"1","preferredName":"Response","preferredDefinition":"Response is any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","longName":"C25755","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EACFDBFA-EFCE-25E6-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-12-09","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"RECIST:Response Evaluation Criteria in Solid Tumors","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E48AB905-C889-6390-E040-BB89AD43301A","latestVersionIndicator":"Yes","beginDate":"2013-08-22","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-08-22","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":"8/31/17 tt transferred context, added registration status and CSI per Round 5 finalization task. 6/3/14 CDE/DEC released for DCP reuse. jc  8/22/13 created for RECIST CRF. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6001371","version":"1","preferredName":"irRECIST Overall Type","preferredDefinition":"A set of criteria for capturing the unidimensional measurements which are used to assess the effect of immunotherapeutic agents on solid tumors. These criteria are based on elements of the Immune-Related Response Criteria (irRC) and Immune-related RECIST (irRECIST)._Including everything._Something distinguishable as an identifiable class based on common qualities.","longName":"6001371v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"3","maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"irCR","valueDescription":"irCR","ValueMeaning":{"publicId":"6001372","version":"1","preferredName":"irCR","longName":"6001372","preferredDefinition":"A complete disappearance of  all measurable and non-measurable lesions. Lymph nodes must decrease to less than 10 mm in short axis. Confirmation of response is not mandatory.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST Complete Response","conceptCode":"C140316","definition":"A complete disappearance of all measurable and non-measurable lesions. Lymph nodes must decrease to < 10 mm in short axis. Confirmation of response is not mandatory.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B46FAD0-75C8-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B46FAD0-75E1-3F97-E053-F662850A260F","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"irPR","valueDescription":"irPR","ValueMeaning":{"publicId":"6001373","version":"1","preferredName":"irPR","longName":"6001373","preferredDefinition":"A decrease of greater than or equal to 30% in TMTB relative to baseline, non-target lesions are irNN, and no unequivocal progression of new non-measurable lesions","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST Partial Response","conceptCode":"C140315","definition":"A decrease of 30% or more in TMTB relative to baseline, non-target lesions are irNN, and no unequivocal progression of new non-measurable lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B46FAD0-75ED-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B46FAD0-7606-3F97-E053-F662850A260F","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"irPD","valueDescription":"irPD","ValueMeaning":{"publicId":"6001374","version":"1","preferredName":"irPD","longName":"6001374","preferredDefinition":"A minimum 20% increase and minimum 5 mm absolute increase in total measured tumor burden compared to nadir, or irPD for non-target or new non-measurable lesions. Confirmation of progression is recommended minimum 4 weeks after the first irPD assessment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST Progressive Disease","conceptCode":"C140319","definition":"A minimum 20% increase and minimum 5 mm absolute increase in total measured tumor burden compared to nadir, or irPD for non-target or new non-measurable lesions. Confirmation of progression is recommended minimum 4 weeks after the first irPD assessment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B46FAD0-7612-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B46FAD0-762B-3F97-E053-F662850A260F","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"irSD","valueDescription":"irSD","ValueMeaning":{"publicId":"6001375","version":"1","preferredName":"irSD","longName":"6001375","preferredDefinition":"A failure to meet criteria for irCR or irPR in the absence of irPD.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST Stable Disease","conceptCode":"C140317","definition":"A failure to meet criteria for irCR or irPR in the absence of irPD.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B46FAD0-7637-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"KUMMEROA","dateModified":"2022-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B46FAD0-7650-3F97-E053-F662850A260F","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"irNE","valueDescription":"irNE","ValueMeaning":{"publicId":"6001376","version":"1","preferredName":"irNE","longName":"6001376","preferredDefinition":"Used in exceptional cases where insufficient data exists.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST Non-Evaluable","conceptCode":"C140320","definition":"Used in exceptional cases where insufficient data exists.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B46FAD0-765C-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B46FAD0-7675-3F97-E053-F662850A260F","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"irND","valueDescription":"irND","ValueMeaning":{"publicId":"6002992","version":"1","preferredName":"irND","longName":"6002992","preferredDefinition":"Used in adjuvant setting when no disease is detected.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST No Disease","conceptCode":"C140321","definition":"Used in adjuvant setting when no disease is detected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F27D4-A19B-6183-E053-F662850AF68C","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F27D4-A1B4-6183-E053-F662850AF68C","beginDate":"2017-10-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"irNN","valueDescription":"irNN","ValueMeaning":{"publicId":"6001383","version":"1","preferredName":"irNN","longName":"6001383","preferredDefinition":"No target disease was identified at baseline and at follow-up the patient fails to meet criteria for irCR or irPD.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"irRECIST No Baseline Disease","conceptCode":"C140318","definition":"No target disease was identified at baseline and at follow-up the patient fails to meet criteria for irCR or irPD.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B4757C3-002F-07ED-E053-F662850A267F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F27D4-A1BE-6183-E053-F662850AF68C","beginDate":"2017-10-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6002991","version":"1","preferredName":"Immune-related Response Evaluation Criteria In Solid Tumors Overall Type","preferredDefinition":"A set of criteria for capturing the unidimensional measurements which are used to assess the effect of immunotherapeutic agents on solid tumors. These criteria are based on elements of the Immune-Related Response Criteria (irRC) and Immune-related RECIST (irRECIST).:Including everything.:Something distinguishable as an identifiable class based on common qualities.","longName":"C140313:C25605:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-related Response Evaluation Criteria In Solid Tumors","conceptCode":"C140313","definition":"A set of criteria for capturing the unidimensional measurements which are used to assess the effect of immunotherapeutic agents on solid tumors based on elements of Immune-related RECIST (irRECIST).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Overall","conceptCode":"C25605","definition":"Including everything.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F27D4-A184-6183-E053-F662850AF68C","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"irRECIST: Immune-related Response Evaluation Criteria in Solid Tumours (RECIST)-2013","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"5B46FAD0-75AE-3F97-E053-F662850A260F","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-10-11","modifiedBy":"KNABLEJ","dateModified":"2018-10-23","changeDescription":"10/23/18 jk chg reg status to Standard for RECIST defined PV list; do not add PVs without checking latest version of guideline. 10/12/17 LS created.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"5635324","version":"1","longName":"RECIST","context":"NCI Standards"},{"publicId":"6006642","version":"1","longName":"irRECIST","context":"NCI Standards"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Best overall response","type":"Preferred Question Text","description":"Best overall response","url":null,"context":"NCI Standards"},{"name":"irRECIST","type":"Alternate Question Text","description":"Best overall response","url":null,"context":"NCI Standards"}],"origin":"irRECIST: Immune-related Response Evaluation Criteria in Solid Tumours (RECIST)-2013","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"72DECCB7-3723-77F7-E053-F662850A43B2","latestVersionIndicator":"Yes","beginDate":"2018-08-07","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-08-07","modifiedBy":"KNABLEJ","dateModified":"2018-10-22","changeDescription":"10/22/18 jk no reuse; upd SN to text.  10/7/18 jk Changed registration status to \"Standard\" per Fall 2018 Content Team review.  8/7/18 jk created based on iRECIST guideline for RECIST FG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}